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1. Introduction {#brb3706-sec-0005}
===============

The suicide behavior comprises the ideation of the suicide, the intent and the suicide (Turecki & Brent, [2016](#brb3706-bib-0038){ref-type="ref"}). Suicide represents today a major public health problem. According to the WHO organization, over 800,000 people die by this cause every year in the world (WHO, [2014](#brb3706-bib-0040){ref-type="ref"}). Even though various risk factors have been identified such as vulnerable age groups, psychiatric disorders, drug and alcohol use, social and economic issues among them (Hegerl, [2016](#brb3706-bib-0015){ref-type="ref"}; Hernandez‐Alvarado et al., [2016](#brb3706-bib-0016){ref-type="ref"}; Johnson, Carver, & Tharp, [2016](#brb3706-bib-0018){ref-type="ref"}; Ventriglio et al., [2016](#brb3706-bib-0039){ref-type="ref"}), there are some exceptions that cannot be explained by these causes (Costanza, Baertschi, Weber, & Canuto, [2015](#brb3706-bib-0004){ref-type="ref"}). In the etiology of suicide behavior, one major issue that still offers a limited understanding is the neurobiological aspect (Lindqvist et al., [2011](#brb3706-bib-0026){ref-type="ref"}). Biomarkers, substances used as indicators of a biological state, represent a useful tool in the diagnosis and prediction of suicide behavior (Le‐Niculescu et al., [2013](#brb3706-bib-0024){ref-type="ref"}; Strimbu & Tavel, [2010](#brb3706-bib-0037){ref-type="ref"}). One of the main biomarkers proposed in association studies with suicide attempted and suicide is a neurotrophin named brain‐derived neurotrophic factor (BDNF; Grah et al., [2014](#brb3706-bib-0012){ref-type="ref"}; Priya, Rajappa, Kattimani, Mohanraj, & Revathy, [2016](#brb3706-bib-0034){ref-type="ref"}).

In the human body, the concentration of BDNF is higher in cerebral tissue than in the blood stream (Hashimoto, [2010](#brb3706-bib-0013){ref-type="ref"}). Of the BDNF present in the circulation, more than a half is originated from brain structures (Rasmussen et al., [2009](#brb3706-bib-0035){ref-type="ref"}). Recently, BDNF has been implicated as a possible biomarker for psychiatric diseases such as schizophrenia, bipolar disorder and major depression, given that BDNF levels are lower in these patients than in healthy subjects (Castren & Kojima, [2017](#brb3706-bib-0003){ref-type="ref"}; Eisen et al., [2015](#brb3706-bib-0007){ref-type="ref"}; Grah et al., [2014](#brb3706-bib-0012){ref-type="ref"}; Hashimoto, [2010](#brb3706-bib-0013){ref-type="ref"}; Kim et al., [2007](#brb3706-bib-0020){ref-type="ref"}; Lee & Kim, [2009](#brb3706-bib-0022){ref-type="ref"}; Priya et al., [2016](#brb3706-bib-0034){ref-type="ref"}). Dwivedi et al. ([2003](#brb3706-bib-0006){ref-type="ref"}) reported a decrease in BDNF levels in patients that completed the suicide. Since then, the interest in BDNF levels as a biomarker in suicide behavior has been on the rise. Furthermore, in suicide attempt, a decrease between serum BDNF levels and patients with this behavior has been observed (Eisen et al., [2016](#brb3706-bib-0008){ref-type="ref"}). At the moment, one meta‐analysis has been conducted to study the association between BDNF levels and suicide behavior (Eisen et al., [2015](#brb3706-bib-0007){ref-type="ref"}); this analysis only included three articles. The findings of this meta‐analysis showed no association between serum BDNF levels and suicide attempt.

Given the hypothesis that the BDNF could be used as a biomarker, we decide to perform a meta‐analysis of BDNF levels measured in two types of samples: plasma, serum for suicide attempt and hippocampus in suicide. To probe this hypothesis, we performed an exploratory study through a meta‐analysis to evaluate the differences between suicide attempters and controls in both in serum and plasma BDNF levels to determine whether the BDNF level could be used as biomarker among individuals with suicide behavior.

2. Methods {#brb3706-sec-0006}
==========

This study was designed as a systematic review and meta‐analysis to evaluate the possible participation of the BDNF level in plasma, serum for suicide attempt and hippocampus tissue for suicide as biomarker in the etiology of suicide. Both methodological approaches were performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines.

The protocol registration in PROSPERO is CRD42016048612.

2.1. Search strategies {#brb3706-sec-0007}
----------------------

The electronic search was carried out in three different databases, PubMed, EBSCO, and ScienceDirect. The literature review covered the period between June and July 2016 and the search was conducted using the queries required to maximize the sensitivity of the literature search, viz.: BDNF plasma levels and suicide (PubMed: 15; EBSCO: 9; ScienceDirect: 880), BDNF serum levels and suicide (PubMed: 16; EBSCO: 9: ScienceDirect: 898), BDNF brain and suicide (PubMed: 125; EBSCO: 82; ScienceDirect: 1,892), BDNF and suicide (PubMed: 133; EBSCO: 100; ScienceDirect: 1,979), BDNF and suicidal behavior (PubMed: 83; EBSCO: 63; ScienceDirect: 785).

2.2. Inclusion and exclusion criteria {#brb3706-sec-0008}
-------------------------------------

The inclusion criteria were the following: (1) That the study had to be published in a peer‐reviewed journal; (2) That the reports were association cases‐control studies type; (3) Reported BDNF concentrations of plasma or serum in suicide attempters; (4) Reported BDNF hippocampal measures in patients with suicide. (5) Studies published in English.

As exclusion criteria: (1) studies lacking the standard derivation of the mean BDNF levels were excluded from the analysis (Grah et al., [2014](#brb3706-bib-0012){ref-type="ref"}; Mansur et al., [2016](#brb3706-bib-0029){ref-type="ref"}; Priya et al., [2016](#brb3706-bib-0034){ref-type="ref"}). We contacted the corresponding authors to obtain the standard deviation and missing data. (2) Studies that provided analysis in different tissue to hippocampus (Martinez, Garakani, Yehuda, & Gorman, [2012](#brb3706-bib-0030){ref-type="ref"}).

2.3. Data extraction {#brb3706-sec-0009}
--------------------

To determine the descriptive characteristic of the studies, we extracted the following data for the systematic review: authors, year of publication, region, ethnic origin, sample size, number of cases and controls, gender, age, levels of BDNF in serum, plasma and brain tissue (hippocampus), and psychiatric diagnosis. Two researchers (Salas‐Magaña and González‐Castro) screened independently each article by title, abstract and full text to determine inclusion and selection of the studies. A consensus of the information was reached.

2.4. Measure of quality {#brb3706-sec-0010}
-----------------------

The studies were assessed using the Grading of Recommendations Assessment, Development and Evaluation Scale system (<http://www.gradeworkinggroup.org>) to evaluate quality. In addition of the quality assessment, the Newcastle‐Ottawa Scale was also applied to the selected studies (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). We made an assessment to distinguish high quality studies from the rest by using a mark of six score points or more.

2.5. Statistical analysis {#brb3706-sec-0011}
-------------------------

We grouped studies according to the type of sample ‐plasma, serum for suicide attempt and hippocampus for suicide‐ and made the comparison for each case. If multiple case‐groups existed within a certain category (e.g., depressed with or without suicide attempt), a collection was made for each of them. For the meta‐analysis, only attempted suicide and completed suicide groups were included, however, the mean age and standard deviation (*SD*) in some cases were taken from the total number of cases. When studies assaying BDNF from brain tissue consisted of multiple analytical sections (e.g., PFC, entorhinal cortex, basolateral nucleus of amygdala \[BLA\], CFS), only the hippocampus data was included in the analysis.

To determine whether BDNF could be used as a biomarker, the outcomes of the meta‐analyses are expressed as standardized mean difference (*d*) and 95% CI (Perroud et al., [2009](#brb3706-bib-0032){ref-type="ref"}). The standardized mean difference was calculated from the mean and *SD* of BDNF levels for cases and control groups. All analyses were conducted in EPIDAT 3.1 software (<http://www.sergas.es/Saude-publica/Epidat-3-1-descargar-Epidat-3-1-(espanol)?print=1>). To assess heterogeneity among studies we used the Dersimonian and Laird\'s *Q* test and inconsistence index (*I* ^2^). Likewise, publication bias was analyzed by the Egger\'s test. A series of analyses was performed according to the type of sample (serum, plasma and brain tissue). The aim of this study was to determine whether BDFN levels were lower in suicide cases (suicide ideation, suicide attempt and completed suicide) than in healthy controls. A sensitivity analysis was performed to assess the influence of each study in the global estimation. Finally, publication bias was explored using the Egger\'s test and shown as funnel plots using the EPIDAT 3.1 Software.

3. Results {#brb3706-sec-0012}
==========

3.1. Study information {#brb3706-sec-0013}
----------------------

In our screening phase, our search strategy retrieved 7,069 potentially relevant studies. Next, we removed 388 duplicated articles, so 6,681 articles were assessed. Figure [1](#brb3706-fig-0001){ref-type="fig"} summarizes the stages of the meta‐analysis in the PRISMA flow chart. The combined data of 16 studies (before the exclusion criteria were applied) are presented in Tables [1](#brb3706-tbl-0001){ref-type="table-wrap"} and [2](#brb3706-tbl-0002){ref-type="table-wrap"}. In the end only nine studies fulfilled our inclusion criteria; these studies were performed in Korea (Kim et al., [2007](#brb3706-bib-0020){ref-type="ref"}; Lee & Kim, [2009](#brb3706-bib-0022){ref-type="ref"}; Lee, Kim, Park, & Kim, [2007](#brb3706-bib-0023){ref-type="ref"}; Park, Lee, Um, & Kim, [2014](#brb3706-bib-0031){ref-type="ref"}); Taiwan (Huang & Lee, [2006](#brb3706-bib-0017){ref-type="ref"}); Turkey (Deveci, Aydemir, Taskin, Taneli, & Esen‐Danaci, [2007](#brb3706-bib-0005){ref-type="ref"}); China (Liang, Zhang, Hong‐Ya, & Lv, [2012](#brb3706-bib-0025){ref-type="ref"}); Canada (Eisen et al., [2016](#brb3706-bib-0008){ref-type="ref"}), and Brazil (Pinheiro et al., [2012](#brb3706-bib-0033){ref-type="ref"}). As a result, in this meta‐analysis we included 246 cases and 601 controls overall, which were distributed in 80 cases and 145 controls for the meta‐analysis of plasma samples; 166 cases and 456 control for the meta‐analysis of serum samples. The meta‐analysis of hippocampal samples was not performed because the measuring units did not coincide in these studies (Dwivedi et al., [2003](#brb3706-bib-0006){ref-type="ref"}; Karege, Vaudan, Schwald, Perroud, & La Harpe, [2005](#brb3706-bib-0019){ref-type="ref"}; Table [1](#brb3706-tbl-0001){ref-type="table-wrap"}).

![Flow‐diagram illustrating the search and inclusion/exclusion criteria used for the meta‐analysis and systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement criteria](BRB3-7-e00706-g001){#brb3706-fig-0001}

###### 

Descriptive characteristics of the studies included in the systematic review and meta‐analysis in plasma and serum

  Reference                                                     Location   Diagnosis   Sample   Units   Cases   Controls                           
  ------------------------------------------------------------- ---------- ----------- -------- ------- ------- ---------- -------- ----- -------- --------
  Lee et al. ([2007](#brb3706-bib-0023){ref-type="ref"})        Korea      MDD         Plasma   pg/ml   28      386.61     362.39   95    819.20   347.05
  Kim et al. ([2007](#brb3706-bib-0020){ref-type="ref"})        Korea      MDD         Plasma   pg/ml   32      430.5      397.00   30    889.40   611.30
  Lee and Kim ([2009](#brb3706-bib-0022){ref-type="ref"})       Korea      MDD         Plasma   pg/ml   20      713.04     236.56   20    709.05   172.12
  Huang and Lee ([2006](#brb3706-bib-0017){ref-type="ref"})     Taiwan     SCZ         Serum    ng/ml   11      14.60      7.02     96    14.17    6.86
  Deveci et al. ([2007](#brb3706-bib-0005){ref-type="ref"})     Turkey     AD          Serum    ng/ml   10      21.20      12.24    26    31.4     8.80
  Liang et al. ([2012](#brb3706-bib-0025){ref-type="ref"})      China      MDD         Serum    ng/ml   31      57.30      9.20     30    113.8    44.4
  Park et al. ([2014](#brb3706-bib-0031){ref-type="ref"})       Korea      MDD         Serum    ng/ml   18      21.93      24.71    33    24.71    7.7
  Pinheiro et al. ([2012](#brb3706-bib-0033){ref-type="ref"})   Brazil     PPAD        Serum    ng/ml   12      2.11       1.42     178   2.37     1.26
  Eisen et al. ([2016](#brb3706-bib-0008){ref-type="ref"})      Canada     MAD         Serum    ng/ml   84      24.21      7.19     93    24.77    7.01

MDD, major depression disorder; SZC, schizophrenia; AD, adjustment disorder; PPAD, postpartum affective disorder; MAD, mood and anxiety disorder.

John Wiley & Sons, Ltd

###### 

Descriptive characteristics of the studies no included in the meta‐analysis

  Reference                                                     Location            Diagnosis                  Sample             Units               Cases   Controls                                                                
  ------------------------------------------------------------- ------------------- -------------------------- ------------------ ------------------- ------- --------------------- ------ ------ ----- --------------------- ------- ------
  Karege et al. ([2005](#brb3706-bib-0019){ref-type="ref"})     Switzerland         MDD, BD                    Hippocampus        ng/g                22      Drug‐free MDD         17.7   2.9    8     Drug‐free             24.5    3.6
  Drug‐free others                                              16.8                3.1                                                                                                                                               
  Drug‐treated MDD                                              23.3                2.2                                                                                                                                               
  Banerjee et al. ([2013](#brb3706-bib-0002){ref-type="ref"})   India               MDD, BD, AD, SCZ, FD, MD   Hippocampus        pg/ml               21                            19.5   ---    19                          44      ---
  Dwivedi et al. ([2003](#brb3706-bib-0006){ref-type="ref"})    EE.UU.              MDD, AD, BD, SCZ           Hippocampus        Optical density     27      Suicide/MDD           1.04   0.20   21                          1.71    0.44
  Suicide/OPD                                                   1.03                0.22                                                                                                                                              
  Hayley et al. ([2015](#brb3706-bib-0014){ref-type="ref"})     Hungary             MDD                        Hippocampus        Optical density     9       Females‐Hippocampus   0.65   ---    10    Females‐Hippocampus   0.55    ---
  10                                                            Males‐Hippocampus   0.40                       9                  Males‐Hippocampus   0.75                                                                            
  Mansur et al. ([2016](#brb3706-bib-0029){ref-type="ref"}0     Brazil              BD                         Plasma             pg/ml               57                                   ---    26                                  ---
  Grah et al. ([2014](#brb3706-bib-0012){ref-type="ref"})       Croatia             AD, MDD                    Serum              ng/ml               96      \(26\) RDD            11.8   ---    106   \(60\) C              13.40   ---
  \(33\) PD                                                     10.7                                           \(25\) RDD         12.80                                                                                               
  \(37\) AD                                                     12.6                                           \(26\) PD          15.70                                                                                               
                                                                                                               \(25\) AD          15.40                                                                                               
  Martinez et al. ([2012](#brb3706-bib-0030){ref-type="ref"})   EE.UU.              MDD                        CFS                pg/ml               18                                   ---    25                                  ---
  Hayley et al. ([2015](#brb3706-bib-0014){ref-type="ref"})     Hungary             MDD                        PFC, hippocampus   Optical density     9       Females                      ---    10    Females                       ---
                                                                PFC                 0.75                                          PFC                 1.40                                                                            
                                                                Hippocampus         0.65                                          Hippocampus         0.55                                                                            
  10                                                            Males                                          9                  Males                                                                                               
                                                                PFC                 0.50                                          PFC                 0.40                                                                            
                                                                Hippocampus         0.40                                          Hippocampus         0.75                                                                            

MDD, major depression disorder; BD, bipolar disorder; AD, adjustment disorder; SZC, schizophrenia; FD, familiar disharmony; MD, marital disharmony; OPD, other psychiatric disorder; RDD, recurrent depressive disorder; MAD, mood and anxiety disorder; PD, psychiatric disorder; PPAD, postpartum affective disorder; PFC, prefrontal cortex; C, control.

John Wiley & Sons, Ltd

3.2. Meta‐analysis of BDNF levels in plasma {#brb3706-sec-0014}
-------------------------------------------

First, we evaluated BDNF levels in plasma and found that values were lower in cases than in controls. The case--control studies analyzing BDNF levels in plasma were 3 (Kim et al., [2007](#brb3706-bib-0020){ref-type="ref"}; Lee & Kim, [2009](#brb3706-bib-0022){ref-type="ref"}; Lee et al., [2007](#brb3706-bib-0023){ref-type="ref"}). The results of the standardized mean difference showed lower BDNF levels in the cases with suicide attempt than in healthy controls (*d *=* *−0.73, 95% CI −1.42 to −0.03 pg/ml, *I* ^2^ = 80.74, *p*(*Q*) \< .01 (Figure [1](#brb3706-fig-0001){ref-type="fig"}a). Our results suggest that BDNF levels are decreased in plasma in patients with suicide behavior when compared to control groups. The Forest plots of the meta‐analysis of BDNF and levels in plasma is showed in the Figure [2](#brb3706-fig-0002){ref-type="fig"}.

![Forest plots of the meta‐analysis of brain‐derived neurotrophic factor levels measured in blood plasma and serum](BRB3-7-e00706-g002){#brb3706-fig-0002}

3.3. Meta‐analysis of BDNF levels in serum {#brb3706-sec-0015}
------------------------------------------

Subsequently, we conducted a meta‐analysis to assess whether BDNF levels in serum were lower in cases than in controls. In this analysis the sum of samples consisted of six studies that evaluated the association between BDNF levels in serum for cases with suicide attempt and controls (Deveci et al., [2007](#brb3706-bib-0005){ref-type="ref"}; Eisen et al., [2015](#brb3706-bib-0007){ref-type="ref"}; Huang & Lee, [2006](#brb3706-bib-0017){ref-type="ref"}; Liang et al., [2012](#brb3706-bib-0025){ref-type="ref"}; Park et al., [2014](#brb3706-bib-0031){ref-type="ref"}; Pinheiro et al., [2012](#brb3706-bib-0033){ref-type="ref"}). The analysis did not show statistical difference in serum BDNF levels between cases and control groups (*d* = −0.51, 95% CI −1.06 to 0.33 ng/ml, *I* ^2^ = 83.79, *p*(*Q*) \< .001 (Figure [1](#brb3706-fig-0001){ref-type="fig"}b). The Forest plots of the meta‐analysis of BDNF and levels in serum is showed in Figure [2](#brb3706-fig-0002){ref-type="fig"}.

3.4. BDNF levels in brain tissue {#brb3706-sec-0016}
--------------------------------

The type of sample of the studies varied. The studies found used different parts of the postmortem brain of suicide victims. We first group the studies according to their similarity in study sample. While some used hippocampus (Banerjee, Ghosh, Ghosh, Bhattacharyya, & Mondal, [2013](#brb3706-bib-0002){ref-type="ref"}; Dwivedi et al., [2003](#brb3706-bib-0006){ref-type="ref"}; Hayley et al., [2015](#brb3706-bib-0014){ref-type="ref"}; Karege et al., [2005](#brb3706-bib-0019){ref-type="ref"}), others utilized BLA and central nucleus of amygdala (Maheu, Davoli, Turecki, & Mechawar, [2013](#brb3706-bib-0028){ref-type="ref"}) and also the *cerebrospinal fluid* (Martinez et al., [2012](#brb3706-bib-0030){ref-type="ref"}).

With respect to the studies with BDNF hippocampal levels the findings the followings. In the study performed in Switzerland by Karege et al. ([2005](#brb3706-bib-0019){ref-type="ref"}), reported a BDNF decrease in suicide victims, regardless of diagnosis, also observed in an American population (Dwivedi et al., [2003](#brb3706-bib-0006){ref-type="ref"}). This decrease was observed also in an Indian population (Banerjee et al., [2013](#brb3706-bib-0002){ref-type="ref"}), even when the sample present several psychiatric diagnoses such as major depress disorder, bipolar disorder and adjustment disorder. In the last study performed in Hungary (Hayley et al., [2015](#brb3706-bib-0014){ref-type="ref"}), the results varied according the gender. The male suicides present significant reductions of BDFN levels, but not female suicides.

4. Discussion {#brb3706-sec-0017}
=============

In this study, we performed a systematic review and meta‐analysis to evaluate whether BDNF levels (serum, plasma for suicide attempt and BDNF level in hippocampus for suicide) were decreased in patients with suicide behavior. Our purpose was to determine whether BDNF could be used as a biomarker among individuals with suicide behavior. In our meta‐analysis of peripheral samples, we found that in plasma but not in serum BDNF levels were decreased in patients with suicide attempt. To the best of our knowledge, this study is the first meta‐analysis showing a decrease in BDNF levels in plasma for this type of patients. Our results support the hypothesis that some neurotrophins are implicated in neuropsychiatric disorders and that BDNF could be implicated in suicide behavior (Eisen et al., [2016](#brb3706-bib-0008){ref-type="ref"}).

A possible explanation for low peripheral BDNF levels in patients with suicide attempt could be that severe stress consequent with attempted suicide may markedly decrease BDNF levels after the attempt. Another probable cause for low peripheral BDNF levels in patients with suicide attempt could be a down‐regulation of BDNF expression derived from a decrease in serotonin function in central level (Ambrus, Lindqvist, Traskman‐Bendz, & Westrin, [2016](#brb3706-bib-0001){ref-type="ref"}). However, the evidence should be taken with caution, since up to now only three studies in the literature have examined BDNF levels in plasma (Eisen et al., [2016](#brb3706-bib-0008){ref-type="ref"}; Kim et al., [2007](#brb3706-bib-0020){ref-type="ref"}; Lee & Kim, [2009](#brb3706-bib-0022){ref-type="ref"}; Lee et al., [2007](#brb3706-bib-0023){ref-type="ref"}) and the assayed sample was small (80 cases and 145 controls).

Second, a different scenario was encountered when the meta‐analysis was addressed to assess BDNF levels in serum. In this case, no significant differences in BDNF concentrations were observed between patients with suicide attempt and controls. Our results are in agreement with a previous meta‐analysis (Eisen et al., [2015](#brb3706-bib-0007){ref-type="ref"}). We could not find a significant association between BDNF in serum and suicide attempt. In this study, we included 168 cases and 326 controls more and we included six publications, three more than those reported in the previous meta‐analysis. The two meta‐analyses showed a no association, between BDNF levels in serum and suicide attempt.

The apparent contradiction in peripheral BDNF levels (decrease level of BDNF in plasma but not in serum) could be explained due the different mechanism that both, serum and plasma have (Fernandes, Molendijk, et al., [2015](#brb3706-bib-0009){ref-type="ref"}; Fujimura et al., [2002](#brb3706-bib-0011){ref-type="ref"}). BDNF is released into the internal jugular vein, suggesting that the brain delivers it to the circulation. Almost three‐quarters of the BDNF present in circulation are originated from brain structures, suggesting that brain is the main contributor to the circulating BDNF (Krabbe et al., [2007](#brb3706-bib-0021){ref-type="ref"}; Rasmussen et al., [2009](#brb3706-bib-0035){ref-type="ref"}). It is known to be stored in human platelets and to circulate in plasma (Lommatzsch et al., [2005](#brb3706-bib-0027){ref-type="ref"}). The literature shows that BDNF in plasma is released upon agonist stimulation (Fujimura et al., [2002](#brb3706-bib-0011){ref-type="ref"}). Based on the above, the alterations in plasma BDNF levels could reflect more specific changes at central nervous system level than alterations in serum BDNF levels. This situation has been previously demonstrated in schizophrenia and bipolar disorders, which are at the same time, part of the risk factors in suicide and suicide behavior (Fernandes, Molendijk, et al., [2015](#brb3706-bib-0009){ref-type="ref"}; Fernandes, Steiner, et al., [2015](#brb3706-bib-0010){ref-type="ref"}; Fujimura et al., [2002](#brb3706-bib-0011){ref-type="ref"}). Then, this assumption could also be true for this major public health problem. However, this asseveration could gain more support from the evidence.

Finally, in this study, we evaluate the BDNF levels in a central way through the meta‐analysis. The brain tissue used in them was the hippocampus (Banerjee et al., [2013](#brb3706-bib-0002){ref-type="ref"}; Dwivedi et al., [2003](#brb3706-bib-0006){ref-type="ref"}; Hayley et al., [2015](#brb3706-bib-0014){ref-type="ref"}; Karege et al., [2005](#brb3706-bib-0019){ref-type="ref"}). But at the moment, the measuring units do not coincide in the different studies, so it is not possible to perform a meta‐analysis of hippocampus BDNF levels in suicide behavior (Fujimura et al., [2002](#brb3706-bib-0011){ref-type="ref"}).

The present study has some limitations. First, although our meta‐analysis involves assessments of BDNF levels in plasma and serum of patients with suicide behavior and includes more studies and subjects than the past meta‐analysis, the number of studies is still small. The number the studies is even smaller than other studies analyzing BDNF levels in other diseases such as bipolar disorder (Fernandes, Molendijk, et al., [2015](#brb3706-bib-0009){ref-type="ref"}) or schizophrenia. Second, the comorbidity in the patients diagnosis, such as schizophrenia, major depress disorder, bipolarity and adjustment disorder, to name some of them, could be considered in the interpretation of the results. In consequence, more studies are necessary to analyze comorbidity of specific groups. Third, the time between the date of suicide attempt and the tissue sampling is not known. We could not analyze the relation between the time of the suicide attempt and BDNF concentrations in plasma or serum. Similarly, it is also necessary to analyze whether the number of suicide attempts is associated with a higher reduction in BDNF levels. At the last, as a methodological observation all the studies performed the measures of plasma and serum by ELISA.

Finally, we believe that altered BDNF levels in plasma observed in the analysis influence remarkably in the suicide attempt and suicide. Therefore, it is important to continue the searching of how this altered levels may be influenced at a central level (Serra‐Millàs, [2016](#brb3706-bib-0036){ref-type="ref"}). Also, it would be necessary evaluate certain factors, like the environment, the family experience and the precedents in childhood and the three stages of suicide behavior.

In summary, the present meta‐analysis suggests potential differences between BDNF levels in plasma and serum and suggests that BDNF could be used as a potential biomarker in suicide attempt. However, as the number of studies included in the present meta‐analysis is limited, future studies are necessary to measure BDNF levels in plasma, so that these results can be confirmed in larger samples and in different populations.
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